FibroGen (FGEN) PT Lowered to $16 at Goldman Sachs, After Receiving CRL from FDA
Tweet
Share
E-mail
Get Alerts FGEN Hot Sheet
Price: $9.71 --0%
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on FibroGen (NASDAQ: FGEN) to $16.00 (from $22.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
- Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
